US-based biotechnology company Mind Medicine (MindMed) has dosed the first subject in the 52-week Phase III Voyage study of ...
Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product ...
纽约 - 专注于开发脑健康疾病治疗方法的生物制药公司Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)被选入纳斯达克生物技术指数 (NBI)。该公司将于2024年12月23日开盘时正式纳入指数。目前,该公司市值约5.3亿美元,根据 InvestingPro 分析,其财务健康状况获得FAIR评级。
Clinical Trials Arena · Catalent / Business Wire. US-based biotechnology company Mind Medicine (MindMed) has dosed the first subject in the 52-week Phase III Voyage study of MM120 orally ...
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its holdings in Mind Medicine (MindMed) Inc.
Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for ...
Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders ...
Charles Schwab Investment Management Inc. grew its holdings in shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Free ...
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel ...
NEW YORK — Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, ...
MindMed has announced the dosing of the first patient in its phase 3 Voyage study of MM120 ODT, a pharmaceutically optimised form of lysergide D-tartrate (LSD) for treating Generalised Anxiety ...
NEW YORK, December 19, 2024--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain ...